-
Mashup Score: 14New-Onset Diabetes: An Early Sign of Pancreatic Cancer? - 3 year(s) ago
Numerous studies have pointed to a link between new-onset diabetes and pancreatic cancer. Now, several large NCI-supported studies are testing ways to pick out those people whose diabetes might be a sign of early pancreatic cancer, when treatments may be more effective.
Source: National Cancer InstituteCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 13New-Onset Diabetes: An Early Sign of Pancreatic Cancer? - 3 year(s) ago
Numerous studies have pointed to a link between new-onset diabetes and pancreatic cancer. Now, several large NCI-supported studies are testing ways to pick out those people whose diabetes might be a sign of early pancreatic cancer, when treatments may be more effective.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Testing Novobiocin in PARP Inhibitor-Resistant Cancers - 3 year(s) ago
The antibiotic novobiocin showed promise as a treatment for cancers with BRCA mutations that have become resistant to PARP inhibitors. It will soon be tested in NCI-supported clinical trials. The drug inhibits a protein called Pol theta. Another Pol theta inhibitor, ART558, was effective in mice with resistant tumors.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Task Force Focuses on Quality of Life for AYAs with Cancer - 3 year(s) ago
Cancer can greatly disrupt the lives of adolescents and young adults, who are already going through major life transitions. A new task force will help researchers gather much-needed data on how cancer and its treatment affect this age group, with the aim of improving their quality of life during and beyond treatment.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7FDA Approves Rylaze for Childhood ALL - 3 year(s) ago
FDA’s approval of a new form of asparaginase called Rylaze should alleviate shortages of Erwinia asparaginase, a key part of treatment for children and adults with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma, a rare cancer that resembles ALL.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Testing Novobiocin in PARP Inhibitor-Resistant Cancers - 3 year(s) ago
The antibiotic novobiocin showed promise as a treatment for cancers with BRCA mutations that have become resistant to PARP inhibitors. It will soon be tested in NCI-supported clinical trials. The drug inhibits a protein called Pol theta. Another Pol theta inhibitor, ART558, was effective in mice with resistant tumors.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 9Red Meat Genetic Signature for Colorectal Cancer - 3 year(s) ago
Researchers have identified a specific pattern of damaged DNA in people with colorectal cancer who ate a lot of red meat. The link between these mutational signatures and the consumption of red and processed meats further implicates diet in the development of colorectal cancer, experts say.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Advances in Melanoma and Other Skin Cancers Research - 3 year(s) ago
This page highlights what’s new and recent research in the treatment of melanoma and other skin cancers, including targeted therapies, immune checkpoint inhibitors, and adoptive cell transfer. Selected NCI-supported programs to address these cancers are also described.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 10Coronavirus Vaccines and People with Cancer - 3 year(s) ago
Dr. Steven Pergam of the Fred Hutchinson Cancer Research Center discusses the importance of COVID-19 vaccination for people being treated for cancer and cancer survivors. This post was updated on April 9, 2021, with additional questions and answers.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Sacituzumab Earns Regular FDA Approval for TNBC - 3 year(s) ago
Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
RT @theNCI: Could a Diabetes Diagnosis Help Detect Pancreatic Cancer Early? https://t.co/4PcpeoVftm #NCICancerCurrentsblog #repost https://…